Zenas BioPharma, Inc. (ZBIO)

NASDAQ: ZBIO · Real-Time Price · USD

31.27

-1.35 (-4.14%)

At close: Aug 28, 2026, 4:00 PM EDT

30.76

-0.51 (-1.63%)

After-hours: Aug 28, 2026, 7:43 PM EDT

Zenas BioPharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-484.38	-377.74	-156.99	-37.12	-119.28
Depreciation & Amortization	0.03	0.06	0.14	0.11	0.08
Loss (Gain) From Sale of Assets	-	0.11	-	-	-
Asset Writedown & Restructuring Costs	201.67	171.67	-	10	1
Loss (Gain) From Sale of Investments	-2.01	-1.93	-0.6	-	-
Stock-Based Compensation	32.73	26.35	10.82	3.5	0.74
Other Operating Activities	23.76	8.2	1.53	1.03	43.85
Change in Accounts Payable	-0.38	-10.04	11.74	-0.42	1.09
Change in Other Net Operating Assets	2.61	10.99	13.69	-7.62	6.88
Operating Cash Flow	-225.97	-172.33	-119.67	-30.53	-65.65
Operating Cash Flow Growth	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Capital Expenditures	-0	-0.02	-0.13	-0.02	-0.2
Sale (Purchase) of Intangibles	-65	-35	-	-	-2
Investment in Securities	-244.41	-216.87	-30.42	-	-
Investing Cash Flow	-309.41	-251.89	-30.55	-0.02	-2.2

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Long-Term Debt Issued	-	-	-	20	-
Net Debt Issued (Repaid)	296.6	-	-	20	-
Issuance of Common Stock	332.52	152.95	240.91	0.12	-
Other Financing Activities	59.87	62.34	-6.33	-	-
Financing Cash Flow	689	215.28	412.96	20.12	59.39

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Foreign Exchange Rate Adjustments	-1.04	-0.25	0.16	0.08	-0.04
Net Cash Flow	152.57	-209.19	262.89	-10.35	-8.5

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Free Cash Flow	-225.97	-172.35	-119.81	-30.55	-65.85
Free Cash Flow Growth	-	-	-	-	-
Free Cash Flow Margin	-22597.40%	-1723.51%	-2396.10%	-61.09%	-
Free Cash Flow Per Share	-4.22	-3.85	-9.08	-19.95	-44.13
Levered Free Cash Flow	-211.39	-143.11	-60.01	-17.64	-
Unlevered Free Cash Flow	-196.23	-138.53	-60.01	-17.64	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Change in Working Capital	2.23	0.95	25.43	-8.04	7.97

SEC Filings: 10-K · 10-Q